Abstract library

51 results for "Mallia".
#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Drs. Anela Blazevic
#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance
Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr John C Leyden
Authors: Leyden J, Sissons M, Goldstein G, ...
#1208 Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Guidelines support an MDT approach to NETs. We present data on the global NET pt perspective regarding MDT care.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Kjell Öberg
#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life
#1220 Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Marianne Pavel
Keywords: Diagnosis
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1372 The Role of Interval CT Scanning in Patients Undergoing Palliative Chemotherapy for Metastatic Neuroendocrine Tumours (NETs)
Introduction: In NET, radiological response to chemotherapy is often delayed and the importance of interval-imaging during treatment has not been determined.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Rowan Miller
Authors: Miller R, Childs A, Gillmore R, Mayer A, ...
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
#1056 Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases
Introduction: The value of surgical resection in the management of pancreatic neuroendocrine tumor (PNET) with liver metastases (LM) is still debated.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Stefano Partelli
Authors: Partelli S, Inama M, Rinke A, Begum N, ...
#1361 Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor
Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Sebastian Krug
Keywords: pNET